Stuart Poulton, EVP, Chief Development Officer at Karyopharm Therapeutics Inc. (KPTI), sold 403 shares at $9.50 ($4K) on 2026-05-14, disclosed to the SEC on 2026-05-15.
Open-market sale of $4k KPTI by EVP, Chief Development Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| KPTI | SELL | 2026-02-19 | $3K | — | Filing → |
| KPTI | SELL | 2025-09-16 | $3K | — | Filing → |
| KPTI | SELL | 2025-07-30 | $835 | — | Filing → |